Once-a-day transplant drug may simplify life for kidney and liver patients

NCT ID NCT02882828

Completed Disease control Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 134 kidney or liver transplant patients who switched from taking tacrolimus twice a day (Prograf) to once a day (Envarsus). Researchers measured drug levels in the blood before and after the switch to see if the once-daily version provides similar exposure. The goal is to make dosing easier and more convenient for patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tacrolimus (Prograf and Envarsus)
What this could lead to: If successful, this could show that switching to once-daily Envarsus maintains stable drug levels, making it easier for transplant patients to manage their medication.
What could go wrong: This is a small, completed Phase 4 study focused on drug levels, not long-term outcomes. Results may not apply to all transplant patients or guarantee better health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLOGRAFT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLOGRAFT

Contacts and locations

Locations

AP-HP

Paris, France
Limoges Hospital

Limoges, 87 042, France
University Hospital of Amiens

Amiens, France
University Hospital of Bordeaux

Bordeaux, France
University Hospital of Lille

Lille, France
University Hospital of Poitiers

Poitiers, France
University Hospital of Reims

Reims, France
University Hospital of Rouen

Rouen, France
University Hospital of Tours

Tours, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.